Yan Xiaodan, Zhao Shuyuan, Feng Xue, Li Xinrui, Zhou Qian, Chen Qiu
Chengdu University of Traditional Chinese Medicine, Chengdu, 610032, China.
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610032, China.
Nutr Metab (Lond). 2024 May 25;21(1):28. doi: 10.1186/s12986-024-00806-y.
Metabolic syndrome (MetS) is a cluster of clinical syndromes that is closely associated with an elevated risk of developing atherosclerotic cardiovascular disease. In a series of animal experiments and clinical trials, crocus sativus and its component crocin have demonstrated promising hypoglycemic effects. However, there is currently insufficient evidence regarding their impact on cardiometabolic parameters. Our study aimed to assess the impact of Crocus sativus and crocin on glycemic control in individuals with metabolic syndrome and associated disorders, as well as their potential effects on improving cardiometabolic parameters. We searched Cochrane Library, PubMed, Embase, and Web of Science databases to ascertain the pertinent randomized controlled trials (RCTs) until December 30, 2023. Q-test and I statistics were utilized to evaluate heterogeneity among the included studies. Data were merged using a random-effects model and presented as (WMD) with a 95% confidence interval (CI). The current comprehensive review and meta-analysis, encompassing 13 RCTs involving a total of 840 patients diagnosed with metabolic syndrome and associated disorders, demonstrates that Crocus sativus was superior to placebo on Hemoglobin A1c(HbA1c) (WMD: -0.31;95% CI [-0.44,-0.19]. P = 0.002) and systolic blood pressure(SBP) (WMD:-7.49;95% CI [-11.67,-3.30]. P = 0.99) respectively. Moreover, Crocus sativus improved fasting blood glucose (FBG) (WMD:-7.25;95% CI [-11.82, -2.57]. P = 0.002) when used crocin and on other chronic diseases. Crocus sativus reduced the total cholesterol (TC) among the metabolic syndromepatients (WMD:-13.64;95%CI [-26.26, -1.03]. P = 0.03). We demonstrated that Crocus sativus exerts beneficial effects on glycemic control and cardiometabolic parameters in individuals with metabolic syndrome and related disorders.
代谢综合征(MetS)是一组临床综合征,与动脉粥样硬化性心血管疾病发生风险升高密切相关。在一系列动物实验和临床试验中,藏红花及其成分藏花素已显示出有前景的降血糖作用。然而,目前关于它们对心脏代谢参数影响的证据不足。我们的研究旨在评估藏红花和藏花素对代谢综合征及相关疾病患者血糖控制的影响,以及它们对改善心脏代谢参数的潜在作用。我们检索了Cochrane图书馆、PubMed、Embase和Web of Science数据库,以确定截至2023年12月30日的相关随机对照试验(RCT)。采用Q检验和I统计量评估纳入研究之间的异质性。数据使用随机效应模型合并,并以加权均数差(WMD)和95%置信区间(CI)表示。当前这项涵盖13项RCT(共涉及840例诊断为代谢综合征及相关疾病的患者)的综合综述和荟萃分析表明,藏红花在糖化血红蛋白(HbA1c)方面优于安慰剂(WMD:-0.31;95%CI[-0.44,-0.19],P = 0.002),在收缩压(SBP)方面也优于安慰剂(WMD:-7.49;95%CI[-11.67,-3.30],P = 0.99)。此外,使用藏花素时,藏红花改善了空腹血糖(FBG)(WMD:-7.25;95%CI[-11.82,-2.57],P = 0.002)以及其他慢性疾病。藏红花降低了代谢综合征患者的总胆固醇(TC)(WMD:-13.64;95%CI[-26.26,-1.03],P = 0.03)。我们证明藏红花对代谢综合征及相关疾病患者的血糖控制和心脏代谢参数具有有益作用。